With the rapid advancement of precision medicine, programmed cell death‐ligand 1 (PD‐L1) expression status in tumor cells has been attracting attention for its relation to the prognostic outcomes associated with EGFR‐TKIs in patients with EGFR‐mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.